Company Research Report: ADVITOS GmbH
1. Company Overview
Name and Mission
- Company Name: ADVITOS GmbH
- Mission: The mission of ADVITOS is to significantly enhance the survival of patients in intensive care units by providing effective multi-organ support systems. Their vision is to establish this support as a standard for millions of patients worldwide.
History and Founding
- Founded: 2004 as Hepa Wash GmbH; renamed ADVITOS GmbH in 2019.
- Founder: PD Dr. med. Bernhard Kreymann, a nephrologist with extensive medical experience in blood purification and dialysis for kidney diseases.
Key People
- Key Person: Dr. Claus Jessen took over as Chief Executive Officer in 2022. Catherine Schreiber, associated for winning the EIT Women Leadership Award 2022.
Headquarters
- Headquarters: Agnes-Pockels-Bogen 1, 80992 München, Germany.
Employees
- Number of Employees: Over 75 employees.
Revenue
- Revenue Information: No information is available.
Recognition
- Known For: ADVITOS is renowned for the ADVOS therapy, a patented system for multi-organ support in intensive care units that integrates liver, kidney, lung support, and extracorporeal blood pH correction in a single device.
2. Products
ADVOS Multi System
- Product Description: The ADVOS multi is an integrated multi-organ support device offering customizable treatments to focus on one or more detoxification organs simultaneously.
Key Features:
1. User Interface: Intuitive and easy-to-use information panel with dialyse-like menu navigation.
2. Support Features: Includes video-based guidance for easy setup and operation, reducing user interaction during treatment.
3. Blood Flow Control: Adjustable blood flow rates from 100 to 500 ml/min to optimize toxin removal.
4. Anticoagulation: Offers systemic and regional anticoagulation; changes during treatment without tubing replacement.
5. Flexible Treatment Duration: Allows intermittent or continuous treatment up to 24 hours.
6. Fluid Management System: Reduces the need for reverse osmosis installation at treatment sites, with an 85-liter container capacity reducing frequent bag changes.
ADVOS Verfahren (Procedure)
- Procedure Description: An advanced extracorporeal blood purification technology for simultaneous support of kidneys, liver, and lungs, along with pH management.
Key Technologies:
1. Human Albumin Dialysis: Uses enriched dialysate for selective toxin removal.
2. pH Adjustment: Facilitates targeted treatment of metabolic or respiratory acidosis.
3. Continuous Detoxification: Unique recirculation of dialysate ensures continuous detoxification.
3. Recent Developments
Product Launches
- New Product Announcement: A major product launch of the next generation of the ADVOS system is scheduled for 04 December 2024 in Hamburg.
Awards and Achievements
- Awards: Won the prestigious Innovationspreis Bayern in 2020 and recognized as the most innovative medical technology company in Germany in 2021.
Partnerships and Collaborations
- Expansion Efforts: Collaborating with German Accelerator Life Sciences to prepare for U.S. market entry and supported by the European Union’s Horizon 2020 Research and Innovation program.
Clinical Application and Studies
- Clinical Trials: ADVOS therapy has been deployed in multiple hospitals across Europe with promising results, including applications in treating COVID-19 patients.
- Workshops and Trainings: Regular workshops are organized to educate healthcare professionals on utilizing the ADVOS systems, with upcoming sessions planned from January to December 2025.
Management and Structural Changes
- Leadership Change: Dr. Claus Jessen appointed as the new CEO of ADVITOS GmbH in 2022.
Strategy and Development
- Regulatory Advances: Achieved quality management certification under DIN EN ISO 13485:2016 and the EU MDR as of 2024 for the ADVOS multi.
This report is structured to present a thorough understanding of ADVITOS GmbH, capturing their core business strategies, technological advancements, and their role in advancing intensive care treatment solutions globally.
